1 day Ago By Defense World Staff
Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) ‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $107.00 price objective on the stock.
Cantor Fitzgerald’s price objective would suggest a potential upside of 17.66% from the stock’s previous close. Several other equities research analysts have also recently commented on the company.
UBS Group cut their target price on Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th.
Royal Bank of Canada reduced their target price on shares of Axsome Therapeutics from $131.00 to $130.00 and set an “outperform” rating for the company in a report on Tuesday, August 6th.
Wells Fargo & Company started coverage on shares of Axsome Therapeutics in a research note on Tuesday, September 3rd. They issued an “overweight” rating and a $140.00 price target on the stock.
Mizuho reissued a “buy” rating and set a $106.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, June 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $130.
00 price target on shares of Axsome Therapeutics in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $124.
57. Check Out Our Latest Stock Report on AXSM Axsome Therapeutics Stock Performance Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) last announced its quarterly earnings data on Monday, August 5th. The company reported ($1.
24) earnings per share for the quarter, beating the consensus estimate of ($1.30) by $0.06.
Axsome Therapeutics had a negative net margin of 105.85% and a negative return on equity of 117.46%.
The business had revenue of $87.17 million for the quarter, compared to analyst estimates of $84.53 million.
Equities analysts anticipate that Axsome Therapeutics will post -4.73 earnings per share for the current year. Insider Buying and Selling In other Axsome Therapeutics news, COO Mark L.
Jacobson sold 47,739 shares of the business’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total transaction of $4,022,488.
14. Following the completion of the sale, the chief operating officer now owns 5,783 shares in the company, valued at approximately $487,275.58.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . In related news, COO Mark L. Jacobson sold 47,739 shares of the stock in a transaction on Friday, August 9th.
The stock was sold at an average price of $84.26, for a total value of $4,022,488.14.
Following the completion of the sale, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at approximately $487,275.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link .
Also, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.
31, for a total transaction of $1,005,870.96. Following the transaction, the director now owns 10,002 shares in the company, valued at $913,282.
62. The disclosure for this sale can be found here . 22.
40% of the stock is owned by company insiders. Institutional Trading of Axsome Therapeutics A number of large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co.
purchased a new position in Axsome Therapeutics during the second quarter worth about $27,000. EntryPoint Capital LLC bought a new position in shares of Axsome Therapeutics in the first quarter worth approximately $35,000. Point72 Asia Singapore Pte.
Ltd. purchased a new stake in Axsome Therapeutics in the second quarter valued at approximately $47,000. Russell Investments Group Ltd.
lifted its position in Axsome Therapeutics by 5,550.0% during the first quarter. Russell Investments Group Ltd.
now owns 791 shares of the company’s stock valued at $63,000 after purchasing an additional 777 shares during the last quarter. Finally, Covestor Ltd grew its stake in Axsome Therapeutics by 54,750.0% in the 1st quarter.
Covestor Ltd now owns 1,097 shares of the company’s stock worth $88,000 after buying an additional 1,095 shares in the last quarter. Hedge funds and other institutional investors own 81.49% of the company’s stock.
About Axsome Therapeutics ( Get Free Report ) Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Read More Five stocks we like better than Axsome Therapeutics How to Know Which Cryptocurrency to Buy: A Guide for Investors Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge What Does a Stock Split Mean? Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
